Floatz logo

Dual-Targeting Her2 And Pd-L1 Car-T Cells

Peritoneal Carcinoma Metastatic

Sichuan UniversityCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Peritoneal Carcinoma Metastatic cohort.

Asset / SponsorPhaseRating
PD-L1 CAR-T cells
Sichuan University
Early Phase 1C

Same molecule, other indications

Dual-Targeting Her2 And Pd-L1 Car-T Cells is also rated in:

Pleural Effusion, MalignantDormant
C
Indicative ·
39 / 100
View asset →
HER2 Positive MalignanciesDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →